Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 10Phase 1/2 6Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 25Active not recruiting 8Terminated 6Recruiting 4Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 4Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Hodgkin Disease 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × carfilzomib × Clear all
NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Columbia University

Phase 1/2 Terminated
23 enrolled 13 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

University of Nebraska

Phase 1/2 Terminated
11 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Criterium, Inc.

Phase 1/2 Terminated
136 enrolled
Plasma cell

Multiple Myeloma

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Columbia University

Phase 1/2 Terminated
14 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01658904 2016-06-01

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 6 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡